Effects of propanolol and nitrates on exercise capacity, respiratory minute volume and capillary oxygen saturation during exercise in cirrhotic patients with portal hypertension

Hepatology Research

Volumn 24, Issue 2, 2002, Pages 152-158

  Premaratna, Ranjan ^a   Sathishchandra, Harsha ^a   Thilakaratna, Yasoma ^a   Shantharaj, W ^b   De Silva, H Janaka ^a  

^a UNIVERSITY OF KELANIYA   (Sri Lanka)

^b North Colombo Teaching Hospital   (Sri Lanka)

Author keywords

Exercise; Hepatic cirrhosis; Minute volume; Portal hypertension; Propranolol

Indexed keywords

HEMOGLOBIN; ISOSORBIDE DINITRATE; NITRIC ACID DERIVATIVE; PROPRANOLOL;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTERIOVENOUS SHUNT; ARTICLE; CAPILLARY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ESOPHAGUS VARICES; EXERCISE; EXERCISE TEST; EXPIRATORY FLOW RATE; HEART EJECTION FRACTION; HUMAN; LUNG MINUTE VOLUME; MALE; OXYGEN SATURATION; PORTAL HYPERTENSION; PRIORITY JOURNAL; PULSE RATE; SPIROMETRY; THORAX RADIOGRAPHY;

EID: 0036788099     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00079-7     Document Type: Article

References (12)

1. Harve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-66.
2. Agusti AG, Roca J, Bosch J, Garcia-Pagan JC, Wagner PD, Rodriguez-Roisin R. Effects of propranolol on arterial oxygen transport to tissues in patients with cirrhosis. Am Rev Respir Dis 1990;142:306-10.
3. Burroughs AK, Bosch J. Clinical manifestations and management of bleeding episodes in cirrhotics. In: Mc Intyre N, Benhamou JP, Bircher J, Rizetto M, Rodes J, editors. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1991:408-25.
4. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332-54.
5. Bosch J, Garcia-Pagan JC, Feu F, Rodes J. Portal hypertension: clinical pathology. In: Arias IM, Boyer JL, Fausto N, Jacoby WB, Schachter D, editors. The Liver: Biology and Pathobiology. New York: Raven Press, 1994:1343-55.
6. Bosch J, D'Amico G, Luca A, Garcia-Pagan JC, Fen F, Escorsell A. Drug therapy for variceal haemorrhage. In: Bosch J, Groszmann RJ, editors. Portal Hypertension: Pathophysiology and Treatment. Oxford: Blackwell, 1994:108-23.
7. Bandi JC, Garcia PJC, Escorsell A, et al. Effect of propranolol on the hepatic haemodynamic response to physical exercise in patients with cirrhosis. Hepatology 1998;28:677-82.
8. Cales P, Grasset D, Ravaud A, et al. Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. Br J Clin Pharmacol 1989;27:530-2.
9. Wood AJJ, Kornhauser DM, Wilkinson GR, Shand DG, Branch RA. The influence of cirrhosis on steady state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet 1978;3:478-87.
10. Groszmann R. Adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good, the bad, the ugly. Gastroenterology 1997;113:1794-7.
11. Maki T, Naveri H, Leinonen H, Sovijarvi A. Effect of beta blocking agents with and without intrinsic sympathomimetic activity on work efficiency in healthy men. Clin Physiol 1996;16:543-50.
12. Bland JM, Altman DG. Measurement error. Br Med J 1996;313:744.